- Home
- MPLX vs TAK Comparison
MPLX vs TAK Comparison
Compare MPLX & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPLX
- TAK
- Stock Information
- Founded
- MPLX 2012
- TAK 1781
- Country
- MPLX United States
- TAK Japan
- Employees
- MPLX N/A
- TAK N/A
- Industry
- MPLX Oil & Gas Production
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- MPLX Energy
- TAK Health Care
- Exchange
- MPLX Nasdaq
- TAK Nasdaq
- Market Cap
- MPLX 52.4B
- TAK 45.8B
- IPO Year
- MPLX 2012
- TAK N/A
- Fundamental
- Price
- MPLX $51.37
- TAK $14.76
- Analyst Decision
- MPLX Buy
- TAK
- Analyst Count
- MPLX 9
- TAK 0
- Target Price
- MPLX $54.33
- TAK N/A
- AVG Volume (30 Days)
- MPLX 1.1M
- TAK 1.9M
- Earning Date
- MPLX 08-05-2025
- TAK 07-30-2025
- Dividend Yield
- MPLX 7.45%
- TAK 4.01%
- EPS Growth
- MPLX 11.58
- TAK N/A
- EPS
- MPLX 4.33
- TAK 0.45
- Revenue
- MPLX $11,380,000,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- MPLX $16.60
- TAK $1.01
- Revenue Next Year
- MPLX $5.00
- TAK $1.04
- P/E Ratio
- MPLX $11.87
- TAK $63.71
- Revenue Growth
- MPLX 5.46
- TAK 7.45
- 52 Week Low
- MPLX $39.95
- TAK $12.58
- 52 Week High
- MPLX $54.87
- TAK $15.43
- Technical
- Relative Strength Index (RSI)
- MPLX 51.52
- TAK 46.62
- Support Level
- MPLX $51.01
- TAK $14.86
- Resistance Level
- MPLX $52.31
- TAK $15.42
- Average True Range (ATR)
- MPLX 0.81
- TAK 0.14
- MACD
- MPLX 0.00
- TAK -0.03
- Stochastic Oscillator
- MPLX 40.80
- TAK 9.47
About MPLX MPLX LP
MPLX is a partnership that owns both pipelines and gathering and processing assets with extensive holdings in the Appalachian region. The asset base is made up of pipeline assets dropped down from Marathon Petroleum, its sponsor, and gathering and processing assets from MarkWest, which it acquired in 2015. MPLX also acquired Andeavor Logistics in 2019.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.